Radionuclide alpha therapy shows promising survival rates in neuroendocrine tumour patients
A targeted radionuclide alpha therapy, 225Ac-DOTATATE, has been shown to have…
A targeted radionuclide alpha therapy, 225Ac-DOTATATE, has been shown to have long-term anti-tumour effects in patients with advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs).